While the ERSPC
found that screening was associated with a 20 percent reduction in prostate cancer mortality, the PLCO found no such benefit.
calismasina dahil olmus ve PKa tantsi almis 247 hastaya radikal prostatektomi yapilmis ve prostatektomi spesmenlerindeki kanserler degerlendirildiginde bu hastalarin %49'unda klinik anlamsiz, indolan kanserler oldugu gorulmustur.
It is essential to await longer follow-up data from the ERSPC
, as well as longer-term data on how treatment and active surveillance affect long-term quality of life, before more general recommendations can be made regarding mass PSA screening," they conclude.
Longer follow-up data from both the ERSPC
and quality-of-life analyses are essential before universal recommendations regarding screening can be made.
However, the ERSPC
is also near to completing additional studies on quality of life and cost-effectiveness and these must be assessed before making a decision about the appropriateness of a national prostate screening policy," Schroder added.
Results published recently from a Swedish population-based trial that was part of the larger ERSPC
study, the Goteborg Study, suggested that PSA screening for prostate cancer reduced prostate cancer-specific mortality by approximately 50 percent, a rate similar to the overall reduction that has occurred in the United States.
After publication of the main ERSPC
results, a participating center (Goteborg, Sweden) reported their results separately.
In contrast, in the multicenter ERSPC
(European Randomized Study of Screening for Prostate Cancer) trial, which involved 182,160 men aged 50-74 years, those aged 55-69 who received PSA testing once every 4 years had a 20% reduction in prostate cancer--specific mortality (but not overall mortality) at 9 years, with the result maintained at 11 years (N.
found that screening reduced the risk of death from prostate cancer by 20 percent, but 1,410 men would need to be screened and 48 treated to prevent one death from prostate cancer at nine years.
Dr Burns replies: Lisa Kaestner is correct in pointing out that in the ERSPC
there was a 20% relative reduction in mortality from prostate cancer, but the other landmark USA-based Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial failed to show a similar mortality benefit over a 7-10-year period.
(European Randomized Study of Screening for Prostate Cancer) randomly assessed 182,000 men aged 50-74 years to PSA testing or usual care (N.
was a landmark study carried out in 7 countries that enrolled 162 000 men with follow-up out to 14 years.